Physicochemical stability and aerosolization performance of mannitol-based microcomposites

[1]  R. Ambrus,et al.  Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam , 2013 .

[2]  H. Larhrib,et al.  Overcoming the undesirable properties of dry-powder inhalers with novel engineered mannitol particles. , 2013, Therapeutic delivery.

[3]  Waseem Kaialy,et al.  Treating mannitol in a saturated solution of mannitol: a novel approach to modify mannitol crystals for improved drug delivery to the lungs. , 2013, International journal of pharmaceutics.

[4]  A. Nokhodchi,et al.  Freeze-Dried Mannitol for Superior Pulmonary Drug Delivery via Dry Powder Inhaler , 2013, Pharmaceutical Research.

[5]  P. Young,et al.  Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy. , 2012, International journal of pharmaceutics.

[6]  H. Larhrib,et al.  Influence of Batch Cooling Crystallization on Mannitol Physical Properties and Drug Dispersion from Dry Powder Inhalers , 2012 .

[7]  R. Ambrus,et al.  Analysis of co-spray-dried meloxicam-mannitol systems containing crystalline microcomposites. , 2011, Journal of pharmaceutical and biomedical analysis.

[8]  R. Ambrus,et al.  Cytotoxicity testing of carrier-based microcomposites for DPI application. , 2011, Die Pharmazie.

[9]  P. Russo,et al.  Leucine enhances aerosol performance of naringin dry powder and its activity on cystic fibrosis airway epithelial cells. , 2011, International journal of pharmaceutics.

[10]  K. Amighi,et al.  Formulation strategy and use of excipients in pulmonary drug delivery. , 2010, International journal of pharmaceutics.

[11]  H. Chan,et al.  Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  N. Urbanetz,et al.  Simultaneous quantitative analysis of ternary mixtures of D-mannitol polymorphs by FT-Raman spectroscopy and multivariate calibration models. , 2010, International journal of pharmaceutics.

[13]  P. Young,et al.  Delivery of antibiotics to the respiratory tract: an update , 2009, Expert opinion on drug delivery.

[14]  I. Larson,et al.  Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  M. C. Bonner,et al.  The characterization and comparison of spray-dried mannitol samples , 2009, Drug development and industrial pharmacy.

[16]  R. Tan,et al.  Analysis of the influence of relative humidity on the moisture sorption of particles and the aerosolization process in a dry powder inhaler , 2008 .

[17]  P. Colombo,et al.  Back to basics: the development of a simple, homogenous, two-component dry-powder inhaler formulation for the delivery of budesonide using miscible vinyl polymers. , 2008, Journal of pharmaceutical sciences.

[18]  F. Hamada,et al.  Anti-fibrotic effect of meloxicam in a murine lung fibrosis model. , 2007, European journal of pharmacology.

[19]  H. Chan,et al.  Influence of Humidity on the Electrostatic Charge and Aerosol Performance of Dry Powder Inhaler Carrier based Systems , 2007, Pharmaceutical Research.

[20]  G. P. Martin,et al.  Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers. , 2007, International journal of pharmaceutics.

[21]  E. Dursun,et al.  Safety of Meloxicam in Aspirin-Hypersensitive Patients with Asthma and/or Nasal Polyps , 2006, International Archives of Allergy and Immunology.

[22]  L. Borgström,et al.  An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[23]  I. Larson,et al.  Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy. , 2005, Journal of pharmaceutical sciences.

[24]  M. Bele,et al.  Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method. , 2005, International journal of pharmaceutics.

[25]  H. Frijlink,et al.  Dry powder inhalers for pulmonary drug delivery , 2004, Expert opinion on drug delivery.

[26]  V. Rudolph,et al.  Interparticle van der Waals force in powder flowability and compactibility. , 2004, International journal of pharmaceutics.

[27]  P. Young,et al.  The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  H. Okamoto,et al.  Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier. , 2004, Chemical & pharmaceutical bulletin.

[29]  M. Tobyn,et al.  Effect of Humidity on Aerosolization of Micronized Drugs , 2003, Drug development and industrial pharmacy.

[30]  Adrian C. Williams,et al.  Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry--exploring preferred orientation effects. , 2002, Journal of Pharmaceutical and Biomedical Analysis.

[31]  D. Beer,et al.  Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. , 2000, Cancer research.

[32]  Y. Kawahito,et al.  Meloxicam inhibits the growth of non-small cell lung cancer. , 2000, Anticancer research.

[33]  Sumby,et al.  Latest advances in the development of dry powder inhalers. , 2000, Pharmaceutical science & technology today.

[34]  J. Rollinger,et al.  Energy/temperature diagram and compression behavior of the polymorphs of D-mannitol. , 2000, Journal of pharmaceutical sciences.

[35]  M. Kondracki,et al.  The effect of steroidal and non-steroidal anti-inflammatory drugs on the cellular immunity of calves with experimentally-induced local lung inflammation. , 1999, Veterinary immunology and immunopathology.

[36]  Hak-Kim Chan,et al.  Influence of Particle Size, Air Flow, and Inhaler Device on the Dispersion of Mannitol Powders as Aerosols , 1999, Pharmaceutical Research.

[37]  G. Buckton,et al.  Characterisation of small changes in the physical properties of powders of significance for dry powder inhaler formulations. , 1997, Advanced drug delivery reviews.

[38]  M. Hindle,et al.  Effects of humidity on the in-vitro aerosol performance aerodynamic size distribution of cromolyn sodium for inhalation , 1996 .

[39]  R. Niven,et al.  The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation , 1996 .

[40]  P. Schmidt,et al.  Influence of excipients and storage humidity on the deposition of disodium cromoglycate (DSCG) in the Twin Impinger , 1996 .

[41]  J. Raper,et al.  How Much Particle Surface Corrugation Is Sufficient to Improve Aerosol Performance of Powders? , 2004, Pharmaceutical Research.

[42]  P. Byron.  United States Pharmacopeia recommendations for the testing of inhalers. , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[43]  Raymond C Rowe,et al.  Handbook of Pharmaceutical Excipients , 1994 .

[44]  C. Lefebvre,et al.  Study of Different Crystalline forms of Mannitol: Comparative Behaviour under Compression , 1987 .